This is a synthetic peptide designed for use in combination with anti-MRPL49 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
MRPL49
Reaktivität: Human, Affe, Ratte
Wirt: Synthetic
BP
Applikationshinweise
Each Investigator should determine their own optimal working dilution for specific applications.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
Konzentration
1 mg/mL
Buffer
Final peptide concentration is 1 mg/mL in PBS.
Handhabung
Avoid repeated freeze-thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
Target
MRPL49
(Mitochondrial Ribosomal Protein L49 (MRPL49))
Hintergrund
This gene encodes coagulation factor VIII, which participates in the intrinsic pathway of blood coagulation, factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. This gene produces two alternatively spliced transcripts. Transcript variant 1 encodes a large glycoprotein, isoform a, which circulates in plasma and associates with von Willebrand factor in a noncovalent complex. This protein undergoes multiple cleavage events. Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc. This binding domain is essential for coagulant activity. Defects in this gene results in hemophilia A, a common recessive X-linked coagulation disorder.
Alias Symbols: C11orf4, L49mt, MGC10656, NOF, NOF1, MRP-L49
Protein Interaction Partner: ASGR2,CALR,CANX,F10,F2,F9,HSPA5,LMAN1,LRP1,MCFD2,PHYH,PROC,PROS1,VWF,CANX,F10,LMAN1,LRP1,PHYH,PROS1,VWF